Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center

Table 1

Demographic data and survival dates: N=10 (BCLC= Barcelona clinic liver cancer; HCC= hepatocellular carcinoma; SD= standard deviation).

	Total cohort; (n=10)	Adrenalectomy; (n=8)	Afterloading; (n=1)	No Therapy; (n=1)
Gender
male	7 (70.0%)	6 (75.0%)	1 (100%)	0
female	3 (30.0%)	2 (25.0%)	0	1 (100.0%)
Age at time of HCC (SD) [years]	60.8 (6.5)	60.9 (6.5)	54	67
Age at time of adrenal metastasis (SD) [years]	63.4 (7.1)	64.4 (7.1)	55	69
Interval since HCC (SD) [months]	30.8 (6.5)	34.0 (7.7)	13	23
		37.0 (8.2) LTx
BCLC stage at time of diagnosis of HCC
A	3 (30.0%)	2 (25.0%)	1 (100%)
B	5 (50.0%)	5 (62.5%)
C	2 (20.0%)	1 (12.5%)		1 (100%)
Amount of HCC nodes at time of diagnosis
1	4 (40.0%)	2 (25.0%)	1 (100%)	1 (100%)
3	1 (10.0%)	1 (12.5%)
multifocal	5 (50.0%)	5 (62.5%)
Size of largest HCC node (SD) [mm]	42.0 (23.0)	47.0 (20.1)	7	10
Primary therapy of HCC
Liver resection	2 (30.0%)	1 (12.5%)	0	1 (100%)
Liver transplantation	7 (70.0%)	7 (87.5%)	0	0
Local ablative therapy	1 (10.0%)	0	1 (100%)	0
Side of adrenal metastasis
right	4 (30.0%)	3 (37.5%)	0	1 (100%)
left	5 (60.0%)	5 (62.5%)	0	0
bilateral	1 (10.0%)	0	1 (100%)	0
Size of adrenal metastasis (SD) [mm]	45.6 (21.4)	45.1 (21.6)	68	27
Type of adrenalectomy
open	7 (70.0%)	7 (87.5%)	-	-
retroperitoneoscopic	1 (10.0%)	1 (12.5%)	-	-
Surgical complications after adrenalectomy		1 (12.5%)
Recurrence rate after adrenal metastasis
After 1 year	-	5 (37.5%)	1 (100%)	-
After 2 years	-	6 (75.0%)	-	-
Type of recurrence
Hepatic	6 (60.0%)	4 (50.0%)	1 (100%)	1 (100%)
Bone	3 (30.0%)	3 (37.5%)	0	0
Pulmonary	2 (20.0%)	2 (25.0%)	0	0
Brain	3 (30.0%)	1 (12.5%)	0	0
Adrenal contralateral	2 (20.0%)	2 (25.0%)	0	0
Time to progress [months]	12.5 (0-28)	19 (4-28); 20 (4-28) LTx	0	9
Survival after HCC [months]	82 (17.5-200)	109.5 (17.5-200)	43	24
		126 (17.5-200)LTx
Survival after adrenalectomy [months]	-	69 (0.5-122)	-	-
		81 (0.5-122) LTx